Author of

• 10984

  +

  P1.22 - Poster Session 1 - Epidemiology, Etiology (ID 166)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Prevention & Epidemiology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10987

    +

    P1.22-003 - Lung Cancer Survival in Southern Tasmania (ID 684)

    09:30 - 09:30  |  Author(s): N. Harkness
    • Abstract

    Background
    Lung cancer incidence and mortality are high in Tasmania; Incidence Mortality Australia (AIHW 2007) 43/100 000 34/100 000 Tasmania (Cancer Registry 2007) 58/100 000 54/100 000 There is limited published data looking at 5 year survival for primary Non-Small Cell Lung Cancer (NSCLC) particularly from Australian cohorts.

    Methods
    Local clinical practice information was collected in a prospective database. Cases presented at a multidisciplinary lung cancer meeting over a 24 month period (April 2006 -March 2008) were analysed. Patients with NSCLC were identified (n=181). Survival data was obtained for all NSCLC cases (n=181/181) via hospital and general practitioner records as well as the Registry of Births, Deaths and Marriages. Lung cancer stage was based on the 6[th] edition IASLC TNM classification. Mortality data and survival times were calculated according to clinical stage.

    Results
    Five year survival was 10.5% (19/181) for all stages of NSCLC. Stratified by stage, 5 year survival was: Stage I 25% (13/52), Stage II 25% (3/12), Stage III 6% (3/52), and Stage IV 0% (0/65). Overall median survival was 7 months and when stratified by stage was: 30 months for Stage I, 5.5 months for Stage II, 9.1 months for Stage III and 3 months for stage IV disease. Patients who underwent surgical resection with curative intent had a 60% 5 year survival (13/22) which is in keeping with other published Australian data.

    Conclusion
    The five year survival rates for Stage II, III and IV NSCLC were comparable with that of internationally published cohorts. In contrast, all-cause mortality rates for Stage I NSCLC appear higher than expected however rates of surgical cure are in keeping with published data.